Description

Cagrilintide is a long-acting amylin analogue developed as a novel investigational peptide for weight management and metabolic regulation. It mimics the physiological functions of the endogenous hormone amylin, which is co-secreted with insulin by pancreatic β-cells. Cagrilintide binds to amylin and calcitonin receptors in the brain, where it enhances satiety, delays gastric emptying, and reduces food intake—contributing to sustained weight loss when combined with lifestyle modifications or GLP-1 receptor agonists.

Warning: For Research Purposes Only. Injectables are delivered in a freeze-dried (powder) state, contained within a sterile vial. Use requires: Bacteriostatic Water for reconstitution.